D. Miles Et Al. , "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer," ANNALS OF ONCOLOGY , vol.32, no.8, pp.994-1004, 2021
Miles, D. Et Al. 2021. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. ANNALS OF ONCOLOGY , vol.32, no.8 , 994-1004.
Miles, D., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C., ... Xu, B.(2021). Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. ANNALS OF ONCOLOGY , vol.32, no.8, 994-1004.
Miles, KAZIM Et Al. "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer," ANNALS OF ONCOLOGY , vol.32, no.8, 994-1004, 2021
Miles, KAZIM Et Al. "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer." ANNALS OF ONCOLOGY , vol.32, no.8, pp.994-1004, 2021
Miles, D. Et Al. (2021) . "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer." ANNALS OF ONCOLOGY , vol.32, no.8, pp.994-1004.
@article{article, author={KAZIM UYGUN Et Al. }, title={Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer}, journal={ANNALS OF ONCOLOGY}, year=2021, pages={994-1004} }